Semaglutide, a GLP-1 Agonist Like 'Ozempic' and its Potential Role as a Preventive Anti-Cancer Agent DOI Open Access
Maher M. Akl

Cell & Cellular Life Sciences Journal, Год журнала: 2024, Номер 9(1), С. 1 - 4

Опубликована: Янв. 1, 2024

This research note explores the potential of Semaglutide, a GLP-1 agonist similar to Ozempic, as preventive anti-cancer agent. It discusses shared pathophysiological features between cancer and diabetes, including insulin resistance, inflammation, oxidative stress, adipokine imbalance. The highlights GLP-1's role in diabetes prevention, its mechanisms, ongoing research. also touches upon promising relationship receptor agonists treatment, focusing on their impact cell proliferation, apoptosis, angiogenesis regulation. Finally, it emphasizes importance establishing optimal dosages for address both prevention.

Язык: Английский

Developing the Theory of Toxic Chemotherapeutic Nutrition for Cancer Cells and Targeting Tumors via Glucose Mutation: Medical Guidance and Integrated Therapeutic Approach DOI Creative Commons
Maher M. Akl, Amr Ahmed

Опубликована: Янв. 18, 2024

Cancer is a complex genetic disease characterized by aberrant cellular behaviors, including uncontrolled growth, invasion, and metastasis. The development of personalized treatment strategies based on genomic profiling has led to improved outcomes. Recent scientific endeavors have focused targeting cancer through metabolic approaches, capitalizing the altered pathways in cells. Glucosodiene polymer, newly derived compound from glucose, shown promising results inhibiting glucose metabolism modifying tumor's microenvironment acidity. Maher Akl Theory "Glucose Mutation" proposes strategic approach target cancerous tumors altering acidity using isomer polymers. goal disrupt activity tumor potentially modify control disease. This manuscript provides an overview vulnerabilities cells, evaluates synthesis chemical structure glucosodiene, documents its safety, explores potential as targeted therapy for treatment. Additionally, subset successful clinical trials presented, focusing case triple-negative breast (TNBC) with Medical Guidance Integrated Therapeutic Approach: Protocol Glucose Mutation via indication Positive Tumor Lysis Syndrome "The mechanisms action glucosodiene cancer, impact metabolism, modulation signaling pathways, immune-enhancing effects, are discussed.

Язык: Английский

Процитировано

4

Semaglutide, a GLP-1 Agonist Like 'Ozempic' and its Potential Role as a Preventive Anti-Cancer Agent DOI Open Access
Maher M. Akl

Cell & Cellular Life Sciences Journal, Год журнала: 2024, Номер 9(1), С. 1 - 4

Опубликована: Янв. 1, 2024

This research note explores the potential of Semaglutide, a GLP-1 agonist similar to Ozempic, as preventive anti-cancer agent. It discusses shared pathophysiological features between cancer and diabetes, including insulin resistance, inflammation, oxidative stress, adipokine imbalance. The highlights GLP-1's role in diabetes prevention, its mechanisms, ongoing research. also touches upon promising relationship receptor agonists treatment, focusing on their impact cell proliferation, apoptosis, angiogenesis regulation. Finally, it emphasizes importance establishing optimal dosages for address both prevention.

Язык: Английский

Процитировано

2